Anebulo Pharmaceuticals, Inc. (ANEB)
| Market Cap | 163.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 23.27M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $7.03 |
| Previous Close | $7.01 |
| Change ($) | 0.02 |
| Change (%) | 0.29% |
| Day's Open | 6.90 |
| Day's Range | 6.87 - 7.03 |
| Day's Volume | 3,324 |
| 52-Week Range | 6.31 - 9.33 |
Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) released its third-quarter fiscal 2021 financial results on Tuesday with a net loss of $555,832 or $0.04 per share. The ...
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from can...
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from can...
A fresh slate of biotech IPOs has filed to go public as the calendar turns toward the second quarter.
Anebulo Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.
About ANEB
Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Our lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. There is no approved medical treatment currently available to specifically alleviate the symptoms of cannabinoid ov... [Read more...]
| Industry Biotechnology | IPO Date May 7, 2021 |
| CEO Daniel Schneeberger, M.D. | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol ANEB |